Effects of intravitreal triamcinolone acetonide injection with and without preservative

British Journal of Ophthalmology

Volumn 91, Issue 9, 2007, Pages 1122-1124

  Maia, Mauricio ^a,b   Farah, Michel Eid ^a   Belfort, Rubens N ^a   Penha, Fernando Marcondes ^a   Lima Filho, Acácio A S ^a   Aggio, Fabio Bom ^a   Belfort Jr , Rubens ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Vision Institute   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; STEROID; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENDOPHTHALMITIS; FEMALE; HUMAN; INFLAMMATION; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRABECULECTOMY;

ADULT; AGED; AGED, 80 AND OVER; DRUG EVALUATION; ENDOPHTHALMITIS; EYE DISEASES; EYE INFECTIONS, BACTERIAL; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 34548336565     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.115386     Document Type: Article

References (17)

1. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
2. Horio N, Horiguchi M, Yamamoto N. Triamcinolone-assisted internal limiting membrane peeling during macular hole surgery. Arch Ophthalmol 2005;123:96-9.
3. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-9.
4. Gilles MC, Simpson JM, Billson FA, et al. Safety of intravitreal injection of triamcinolone: results from a clinical trial. Arch Ophthalmol 2004;122:336-42.
5. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004;242:184-8.
6. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as a treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:782-9.
7. Jonas JB, Kreissig I, Spandau UH, et al. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-80.
8. Lang Y, Leibu R, Shoham N, et al. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724-31.
9. Nelson ML, Tennant MT, Sivaligan A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone injection. Retina 2003;23:686-91.
10. Dierks D, Lei B, Zhang K, et al. Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch Ophthalmol 2005;123:1563-9.
11. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-5.
12. Kim H, Csaky KG, Gravlin L, et al. Safety and pharmakynetics of preservative-free triamcinolone acetonide formulation for intravitreous administration. Retina 2006;26:523-30.
13. Morrison VI, Koh HJ, Cheng L, et al. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 2006;26:339-44.
14. Bakri SJ, Shah A, Falk NS, et al. Intravitreal preservative-free triamcinolone acetonide for treatment of macular edema. Eye 2005;19:686-8.
15. Peyman GA, Herbst R. Bacterial endophthalmitis treatment with intraocular injection of gentamicin and dexamethasone. Arch Ophthalmol 1974;91:416-23.
16. Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology 2000;107:486-92.
17. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:3-19.